Veeva Systems Inc - Class A NYSE:VEEV Price, Chart, News & Insight

Veeva Falls 5% Despite Strong Earnings Beat, Raised Guidance and Accelerating AI Strategy

Veeva Systems (VEEV) fell 5% in premarket trading despite reporting another strong quarter that exceeded expectations across revenue, earnings, and profitability metrics while raising full-year guidance. The decline suggests investors may have entered earnings with exceptionally high expectations given Veeva's strong positioning in healthcare software and artificial intelligence.

The life sciences cloud software leader reported first-quarter revenue of $882.9 million, up 16% year-over-year, while subscription revenue grew 15% to $730.2 million. Profitability remained outstanding, with operating income rising 17% to $273.1 million and diluted earnings per share increasing 15% to $1.57. Non-GAAP earnings per share reached $2.24, comfortably ahead of the prior year's $1.97.

Management highlighted broad-based growth across its business and continued momentum in both its commercial and development cloud offerings. One of the most notable achievements was the addition of 27 new Vault CRM customers during the quarter, bringing the total number of live customers to more than 150 as Veeva continues replacing legacy CRM systems throughout the pharmaceutical industry.

Investors were also encouraged by rapid progress in the company's AI initiatives. Following the acquisition of Ostro, Veeva now provides conversational AI solutions to more than 50 pharmaceutical brands. Management also announced that Vault AI is scheduled to expand across all Vault applications later this year, while Veeva Falcon, its new agentic AI platform for clinical, regulatory, and safety workflows, is expected to begin early adopter deployment in November.

Reflecting the strong quarter, Veeva raised its full-year fiscal 2027 outlook. The company now expects revenue of $3.64 billion, non-GAAP operating income of approximately $1.61 billion, and non-GAAP earnings per share of about $9.05. Management emphasized that customer interest in AI-powered productivity solutions continues to grow rapidly across the life sciences industry.

Despite these positives, investors may have been looking for an even larger increase to guidance given the company's strong execution and growing AI opportunity. Veeva's shares have historically traded at premium valuations due to its dominant market position, high margins, recurring revenue model, and consistent growth. In such cases, even excellent results can trigger selling if they fail to substantially exceed already elevated expectations.

Importantly, there was little in the report to indicate any operational weakness. Revenue growth remained healthy, margins stayed exceptionally strong, guidance was raised, and AI adoption appears to be accelerating. The stock's decline appears driven more by valuation and investor expectations than by any deterioration in the company's business fundamentals.

Overall, Veeva delivered another high-quality quarter with strong growth, expanding AI capabilities, increasing customer adoption, and higher guidance. The premarket weakness appears to reflect a market that expected perfection from one of the software sector's most highly regarded companies.

💬 🔗

The Investor 06-04-26

5 Cash-Rich Fortresses with War Chests That Could Withstand the Market Chaos

Uncover the 5 cash-rich fortresses built to survive market turbulence and geopolitical tensions with strong war chests.

(thesmartinvestor.com.sg)

💬 🔗

European Investor 04-09-26

Veeva Systems announced the acquisition of Ostro, an AI-driven brand engagement platform for the life sciences industry, in a deal valued at approximately $100 million in cash and equity retention grants.

Ostro’s technology enables pharmaceutical brands to provide patients and healthcare professionals with real-time answers through AI-powered chat interfaces on brand websites. The platform uses conversational AI, semantic search and industry-specific compliance controls to deliver responses drawn from approved medical, legal and regulatory (MLR) materials.

Following the acquisition, Ostro will operate as an independent unit led by its CEO Chase Feiger. Veeva plans to integrate Ostro over time with its Commercial Cloud applications to connect digital engagement with field sales and medical interactions, helping life sciences companies improve customer engagement and access to trusted health information.
PRNewswire

💬 🔗

European Investor 03-10-26

Veeva Systems announced that AOP Health will standardize its global operations on the Veeva Industry Cloud for Life Sciences to connect research, development, quality, commercial and data functions on a single platform.

By adopting applications across the Veeva Vault Platform—including Development Cloud, Quality Cloud, Commercial Cloud and Data Cloud—AOP Health aims to streamline operations, eliminate data silos and accelerate the development and delivery of treatments for rare diseases and critical care conditions.

The unified platform will support collaboration across clinical, regulatory, safety and quality teams while improving coordination between commercial and medical functions. Veeva said the integrated cloud strategy will help AOP Health scale globally and speed the delivery of therapies to patients.
PRNewswire

💬 🔗

European Investor 03-10-26

Veeva Systems Inc. (NYSE: VEEV) announced that more than 125 customers worldwide are now live on its next-generation Vault CRM platform, marking growing adoption of its AI-enabled customer relationship management system for the life sciences industry.

The customers include several top 20 biopharmaceutical companies as well as organizations across the United States, Europe, and Japan. Vault CRM is designed to support commercial and medical teams throughout the full product lifecycle, from product launch preparation to the management of mature brands.

The platform forms part of the Vault CRM Suite, which also includes applications such as Events Management, Service Center, Campaign Manager, and Patient CRM. Veeva said the system combines industry-specific workflows, compliance features, and AI capabilities to support complex customer engagement across global biopharma markets.

Following the increasing adoption of Vault CRM, the company also updated the end-of-support timeline for its legacy Veeva CRM platform, moving the date from September 2030 to the end of December 2029.

PRNewswire

💬 🔗

WS Investor 03-04-26

Veeva Systems has announced the launch of Veeva eSource, a new application within its SiteVault platform aimed at eliminating paper-based processes and streamlining clinical trial data flow at research sites. The solution is designed to reduce manual work, improve data quality, and accelerate the movement of clinical data from sites to sponsors.

Veeva eSource enables direct digital data capture at the site, integrates with electronic health records (EHRs), and supports automated data transfer into electronic data capture (EDC) systems. By removing duplicate data entry and enabling bidirectional integration between eSource and EDC, the application reduces errors, minimizes quality control workload, and eliminates the need for traditional source data verification. The result is a more efficient clinical trial process that allows site staff and sponsors to focus more on patients and study execution.

The new application is part of the Veeva SiteVault platform and requires SiteVault CTMS for use. Veeva plans to make eSource available to early adopters in the second half of 2026, positioning it as a key step toward fully connected, straight-through clinical data flow across the trial ecosystem.

Source: PR Newswire

💬 🔗

The Investor 01-29-26

Veeva Systems released new industry research showing that establishing an AI-ready data and technology foundation has become the top priority for consumer packaged goods (CPG) companies. According to the State of AI in Consumer Goods Report, 82% of surveyed organizations are consolidating legacy systems or moving to unified platforms to standardize data and processes and improve AI readiness.

The study also found that 72% of CPG companies are using, preparing for, or planning to adopt agentic AI, particularly in manufacturing operations. However, progress is constrained by compliance and security concerns, high costs and resource limitations, and integration challenges. Manual processes remain widespread, increasing operational risk, while respondents highlighted AI-powered predictive analytics as critical for improving quality, compliance, and decision-making. The research underscores that successful AI adoption requires coordinated investments in people, processes, and high-quality data infrastructure.

Source: PR Newswire

💬 🔗

WS Investor 01-27-26

Veeva Systems and BioMarin Pharmaceutical have formed a long-term enterprise strategic partnership, expanding their existing relationship. The agreement is designed to help BioMarin increase speed, agility, and operational efficiency across drug development and commercialization by further leveraging Veeva’s software, data, services, and consulting capabilities, with the aim of bringing innovative therapies to patients more quickly.

Source: Veeva Systems, PR Newswire

💬 🔗

WS Investor 01-08-26

Novo Nordisk’s International Operations unit committed to adopting Veeva Vault CRM, selecting the platform to support next-generation commercial execution powered by agentic AI. The move expands the companies’ partnership and provides Novo Nordisk with a global, compliant CRM foundation to enhance engagement across personal and digital channels.

Source: Veeva Systems, Novo Nordisk, PR Newswire

💬 🔗

Global Finance News 01-07-26

Veeva Systems announced that its board has approved a new share repurchase program authorizing the company to buy back up to $2 billion of its Class A common stock. The program, which has a two-year term, allows repurchases through open market transactions, privately negotiated deals, or other permitted methods, including Rule 10b5-1 trading plans. Management emphasized that the initiative reflects Veeva’s strong cash generation, disciplined operations, and confidence in its long-term growth strategy, while preserving flexibility to continue investing in product innovation and customer success.

Source: Veeva Systems press release, January 5, 2026 (PR Newswire).

💬 🔗

The Investor 01-06-26

NYSE:VEEVFollow

5 Cash-Rich Fortresses with War Chests That Could Withstand the Market Chaos

NYSE:VEEV